Literature DB >> 20718413

Thermodynamic analysis of the molecular interactions between amyloid beta-peptide 42 and (-)-epigallocatechin-3-gallate.

Shi-Hui Wang1, Fu-Feng Liu, Xiao-Yan Dong, Yan Sun.   

Abstract

One of the key factors of Alzheimer's disease (AD) is the conversion of amyloid beta-peptide (Abeta) from its soluble random coil form into various aggregated forms. (-)-Epigallocatechin-3-gallate (EGCG) has been proved effective in preventing the aggregation of Abeta, but the thermodynamic mechanisms are still unclear. In this work, isothermal titration calorimetry (ITC) was utilized to study the interactions between Abeta42 and EGCG at different temperatures, salt concentrations, pH values, and EGCG and Abeta42 concentrations. Molecular dynamics (MD) simulations were performed to study the hydrogen bonding between Abeta42 and EGCG. The results indicate that the binding stoichiometry N is linearly related to the EGCG/Abeta42 ratio. Hydrophobic interaction and hydrogen bonding are both substantial in the binding process, but the extent of their contributions changes with experimental conditions. Namely, the predominant interaction gradually shifts from a hydrogen bonding to a hydrophobic interaction with the increase of the EGCG/Abeta42 ratio, resulting in a transition of the binding from enthalpy-driven to entropy-driven. This experimental observation is validated by the MD simulations. The binding of EGCG to Abeta42 can be promoted by increasing temperature and salt concentration and changing pH away from Abeta42's pI. The findings have provided new insight into the molecular interactions between Abeta42 and EGCG from a thermodynamic perspective and are expected to facilitate the research on the inhibition of Abeta42 aggregation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20718413     DOI: 10.1021/jp1001435

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  20 in total

Review 1.  Amyloid β Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies.

Authors:  Jessica Nasica-Labouze; Phuong H Nguyen; Fabio Sterpone; Olivia Berthoumieu; Nicolae-Viorel Buchete; Sébastien Coté; Alfonso De Simone; Andrew J Doig; Peter Faller; Angel Garcia; Alessandro Laio; Mai Suan Li; Simone Melchionna; Normand Mousseau; Yuguang Mu; Anant Paravastu; Samuela Pasquali; David J Rosenman; Birgit Strodel; Bogdan Tarus; John H Viles; Tong Zhang; Chunyu Wang; Philippe Derreumaux
Journal:  Chem Rev       Date:  2015-03-19       Impact factor: 60.622

2.  Site specific interaction of the polyphenol EGCG with the SEVI amyloid precursor peptide PAP(248-286).

Authors:  Nataliya Popovych; Jeffrey R Brender; Ronald Soong; Subramanian Vivekanandan; Kevin Hartman; Venkatesha Basrur; Peter M Macdonald; Ayyalusamy Ramamoorthy
Journal:  J Phys Chem B       Date:  2012-03-07       Impact factor: 2.991

3.  Mechanisms of transthyretin inhibition of β-amyloid aggregation in vitro.

Authors:  Xinyi Li; Xin Zhang; Ali Reza A Ladiwala; Deguo Du; Jay K Yadav; Peter M Tessier; Peter E Wright; Jeffery W Kelly; Joel N Buxbaum
Journal:  J Neurosci       Date:  2013-12-11       Impact factor: 6.167

4.  Synthetic Flavonoids, Aminoisoflavones: Interaction and Reactivity with Metal-Free and Metal-Associated Amyloid-β Species.

Authors:  Alaina S DeToma; Janarthanan Krishnamoorthy; Younwoo Nam; Hyuck Jin Lee; Jeffrey R Brender; Akiko Kochi; Dongkuk Lee; Valentina Onnis; Cenzo Congiu; Stefano Manfredini; Silvia Vertuani; Gianfranco Balboni; Ayyalusamy Ramamoorthy; Mi Hee Lim
Journal:  Chem Sci       Date:  2014-12-01       Impact factor: 9.825

5.  The Effect of (-)-Epigallocatechin-3-Gallate on the Amyloid-β Secondary Structure.

Authors:  Atanu Acharya; Julia Stockmann; Léon Beyer; Till Rudack; Andreas Nabers; James C Gumbart; Klaus Gerwert; Victor S Batista
Journal:  Biophys J       Date:  2020-06-10       Impact factor: 4.033

6.  Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.

Authors:  Kathrin Andrich; Ute Hegenbart; Christoph Kimmich; Niraja Kedia; H Robert Bergen; Stefan Schönland; Erich Wanker; Jan Bieschke
Journal:  J Biol Chem       Date:  2016-12-28       Impact factor: 5.157

7.  The Effect of (-)-Epigallo-catechin-(3)-gallate on Amyloidogenic Proteins Suggests a Common Mechanism.

Authors:  Kathrin Andrich; Jan Bieschke
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

8.  Insights into antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-associated amyloid-β species.

Authors:  Suk-Joon Hyung; Alaina S DeToma; Jeffrey R Brender; Sanghyun Lee; Subramanian Vivekanandan; Akiko Kochi; Jung-Suk Choi; Ayyalusamy Ramamoorthy; Brandon T Ruotolo; Mi Hee Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

Review 9.  Natural compounds may open new routes to treatment of amyloid diseases.

Authors:  Jan Bieschke
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

10.  Comparison of three amyloid assembly inhibitors: the sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01.

Authors:  Sharmistha Sinha; Zhenming Du; Panchanan Maiti; Frank-Gerrit Klärner; Thomas Schrader; Chunyu Wang; Gal Bitan
Journal:  ACS Chem Neurosci       Date:  2012-03-07       Impact factor: 5.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.